Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 4,99 € (+1 060,47 %). La médiane est de 4,99 € (+1 060,47 %).
| Acheter |
4 |
| Conserver |
3 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Cresco Labs strengthens presence in Pennsylvania with purchase of PharmaCann for $50 million
Cresco Labs has acquired PharmaCann Penn for $50 million, gaining nine operational medical marijuana dispensaries in Pennsylvania. The payment was made in cash and via a seller note on a debt- and cash-free basis with a normalized target working capital level. Cresco expects the transaction to boost revenue, margins and cash flow and now operates in the state as both a retail and wholesale operator, running dispensaries under the Sunnyside brand and maintaining cultivation and wholesale activities. » Plus sur de.investing.com
Cresco Labs beats Q2 expectations, but stock remains under pressure
Cresco Labs reported Q2 2026 revenue of $173.34 million and adjusted EPS of -$0.01, with both metrics topping analyst expectations. Adjusted EBITDA rose to $40 million (23% margin) and adjusted gross profit was $89 million (52% margin), while operating cash flow amounted to $15 million. The stock is trading near its 52-week low as investors weigh continued negative earnings, a only flat outlook for Q3 (around $173 million in revenue) and persistent pressures in the cannabis sector. Management sees growth potential in Pennsylvania, Ohio and Kentucky and a positive impact from possible federal reform, but warns of risks from competition, pricing pressure and regulatory uncertainty. » Plus sur de.investing.com
Cresco Labs: analysts expect smaller quarterly loss on declining revenue on May 8
Cresco Labs will report results for the quarter ended March 31, 2026, on May 8, 2026. Four analysts on average estimate a loss of -0.023 USD per share (prior year -0.060 CAD), and six analysts forecast revenue of about 148.9 million USD (prior year 237.8 million CAD). For the current fiscal year, median analyst expectations are a loss of -0.075 USD per share and revenue of about 620.8 million USD (prior year 916.4 million CAD). » Plus sur finanzen.net
Cresco Labs launches at-the-market stock program for around US$100 million
Cresco Labs has established an at-the-market (ATM) program to permit the sale of subordinate voting shares totaling up to approximately US$100 million. A distribution agreement has been entered with Haywood Securities; no shares have been issued yet. Net proceeds are intended primarily for general corporate purposes and potential acquisitions. Sales will occur on the Canadian Securities Exchange and are not registered for a U.S. public offering. » Plus sur de.investing.com
Cresco Labs sells California business as part of strategic realignment
Cresco Labs has announced the sale of its operations in California to strengthen its balance sheet and cash flow, and to focus on higher-margin core markets. CEO Charlie Bachtell cited structural challenges and price pressure in the California market as reasons for the withdrawal. Analysts see uncertain short-term growth prospects, while the company continues to distribute its premium brand FloraCal in the US. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 152,54 M | 8,55 % |
| Bénéfice brut | 70,17 M | 3,77 % |
| Bénéfice net | -10,98 M | 24,42 % |
| EBITDA | 9,14 M | 46,04 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 156,67 M € |
Nombre d'actions | 361,07 M |
Plus haut/bas sur 52 semaines | 2,09 € - 0,42 € |
| Dividendes | Non |
Bêta | 1,72 |
Ratio P/E | -1,67 |
Ratio PEG | 0,01 |
Ratio P/B | 0,51 |
Ratio P/S | 0,26 |
Profil de l'entreprise
Cresco Labs Inc. et ses filiales cultivent, fabriquent et vendent des produits de cannabis à usage récréatif et médical aux États-Unis. Ils proposent du cannabis sous forme de fleurs, de stylos vape, de résines vivantes, de stylos jetables et d'extraits sous la marque Cresco ; de cartouches vape, de stylos vape, de fleurs, de popcorn, de shake, de pré-roulés, de shorties et de concentrés sous la marque High Supply ; de vapes et de gummies sous la marque Good News ; de vapes et de comestibles sous la marque Wonder Wellness Co ; et de teintures, de capsules, de baumes et d'huiles sublinguales sous la marque Remedi, ainsi que des produits de cannabis sous la marque Reserve. La société propose également des fleurs de cannabis sous la marque FloraCal ; des confiseries au chocolat et au caramel, des gummies aux fruits, des bonbons durs et du taffy sous la marque Mindy's Edibles, et concède sous licence la marque Kiva, qui produit des comestibles infusés au cannabis, notamment des confiseries au chocolat, des gummies, des menthes et des tartelettes. En outre, la société propose des comestibles infusés au cannabis sous la marque Sunnyside. Au 27 janvier 2022, elle possédait et exploitait 48 dispensaires. La société a été constituée en 1990 et son siège social se situe à Chicago, dans l'Illinois.
| Nom | Cresco Labs |
| PDG | Charles Bachtell |
| Siège social | Chicago,
il États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Produits pharmaceutiques |
| Introduction en bourse | 03/12/2018 |
| Employés | 2 900 |
Deep Dive
Symboles boursiers
| Bourse | Symbole |
|---|---|
Cnq | CL.CN |
Pnk | CRLBF |
Frankfurt | 6CQ.F |
Düsseldorf | 6CQ.DU |
München | 6CQ.MU |